Trial results
$RARE — DTX301 (avalotcagene ontaparvovec)
Ultragenyx Pharmaceutical Inc. (RARE) DTX301 (avalotcagene ontaparvovec): trial results in Ornithine transcarbamylase deficiency, 2027.
The catalyst
"Data are expected in the first half of 2027."
— Ultragenyx Pharmaceutical Inc., 8-K filed 2026-11-03 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.
- Event id
RARE-DTX301AVALOT-2026- Company
- Ultragenyx Pharmaceutical Inc.
- Kind
- Trial results
- Indication
- Ornithine transcarbamylase deficiency
- Window
- 2027-01-01 – 2027-06-30
- Status
- dropped
The bar
No bar has been published for this event yet.
Verdicts
No verdict has been published for this event yet.